Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

Andrew X. Zhu; Richard S. Finn; Peter R. Galle; Josep M. Llovet; Masatoshi Kudo

doi:10.1016/S1470-2045(19)30165-2

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

Andrew X. Zhu, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Masatoshi Kudo

Research output: Contribution to journal › Letter › peer-review

44 Scopus citations

Original language	English
Pages (from-to)	e191
Journal	The Lancet Oncology
Volume	20
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(19)30165-2
State	Published - Apr 2019

Access to Document

10.1016/S1470-2045(19)30165-2

Cite this

@article{084456c25a384e3b9927412a900153d5,

title = "Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein",

author = "Zhu, {Andrew X.} and Finn, {Richard S.} and Galle, {Peter R.} and Llovet, {Josep M.} and Masatoshi Kudo",

note = "Funding Information: AXZ reports grants from Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, and Novartis, and consultancy fees and advisory roles for AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Eli Lilly, Exelixis, Merck, Novartis, and Roche Genentech. RSF reports consultancy fees for AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Pfizer, Merck, Novartis, Roche Genentech, and Exelixis. PRG reports advisory board and lecture fees from Bayer, Bristol-Myers Squibb, MSD, Merck, Sirtex, AstraZeneca, Sillajen, and Eli Lilly. JML reports grants from Bayer Healthcare, Bristol-Myers Squibb, Eisai, Ipsen, Blueprint, and Incyte, and personal fees from Eli Lilly, Bayer Healthcare, Bristol-Myers Squibb, Eisai, Blueprint, Incyte, Celsion, Exelixis, Glycotest, Ipsen, Merck, Navigant, Leerink Swann, Midatech, Fortress Biotech, Spring Bank Pharmaceuticals, and Nucleix. MK reports grants from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, AbbVie, Medico's Hirata, Astellas, and Bristol-Myers Squibb, and has served on advisory boards for Bayer, Eisai, MSD, Ajinomoto, Kowa, Bristol-Myers Squibb, Chugai, Taiho, Eisai, and Ono.",

year = "2019",

month = apr,

doi = "10.1016/S1470-2045(19)30165-2",

language = "English",

volume = "20",

pages = "e191",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - Ramucirumab in advanced hepatocellular carcinoma in REACH-2

T2 - the true value of α-fetoprotein

AU - Zhu, Andrew X.

AU - Finn, Richard S.

AU - Galle, Peter R.

AU - Llovet, Josep M.

AU - Kudo, Masatoshi

N1 - Funding Information: AXZ reports grants from Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, and Novartis, and consultancy fees and advisory roles for AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Eli Lilly, Exelixis, Merck, Novartis, and Roche Genentech. RSF reports consultancy fees for AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Pfizer, Merck, Novartis, Roche Genentech, and Exelixis. PRG reports advisory board and lecture fees from Bayer, Bristol-Myers Squibb, MSD, Merck, Sirtex, AstraZeneca, Sillajen, and Eli Lilly. JML reports grants from Bayer Healthcare, Bristol-Myers Squibb, Eisai, Ipsen, Blueprint, and Incyte, and personal fees from Eli Lilly, Bayer Healthcare, Bristol-Myers Squibb, Eisai, Blueprint, Incyte, Celsion, Exelixis, Glycotest, Ipsen, Merck, Navigant, Leerink Swann, Midatech, Fortress Biotech, Spring Bank Pharmaceuticals, and Nucleix. MK reports grants from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, AbbVie, Medico's Hirata, Astellas, and Bristol-Myers Squibb, and has served on advisory boards for Bayer, Eisai, MSD, Ajinomoto, Kowa, Bristol-Myers Squibb, Chugai, Taiho, Eisai, and Ono.

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85063580401&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30165-2

DO - 10.1016/S1470-2045(19)30165-2

M3 - Letter

C2 - 30942178

AN - SCOPUS:85063580401

SN - 1470-2045

VL - 20

SP - e191

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -